Nektar Therapeutics (NKTR.OQ)
Bristol-Myers Squibb Co said on Tuesday it would evaluate the use of its blockbuster cancer immunotherapy Opdivo in combination with an experimental drug from Nektar Therapeutics to treat multiple cancers.
* Myers Squibb and Nektar Therapeutics announce Oncology clinical collaboration to evaluate combination of Opdivo (nivolumab) and NKTR-214
* Nektar Therapeutics reports financial results for the second quarter of 2016
CORRECTED-BRIEF-Nektar Therapeutics, Daiichi Sankyo Europe sign licensing deal for breast cancer drug
* Nektar Therapeutics says entitled to an upfront payment of $20 million as well as an additional $60 million in milestone payments
* In case of pre-conditional approval termination of deal, nektar would be obligated to pay daiichi a $12.5 million termination payment - sec filing Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1-646-223-8780)
* Nektar therapeutics reports financial results for the first quarter of 2016
|Takeda Pharmaceutical Co Ltd (4502.T)||¥4,858||-38.00|
|Eisai Co., Ltd (4523.T)||¥6,368||-99.00|
|NOF CORPORATION (4403.T)||¥1,020||+2.00|
|Dr.Reddy's Laboratories Ltd (REDY.NS)||Rs3,200.35||+9.65|
|Novo Nordisk A/S (NOVOb.CO)||kr.290.00||+1.30|
|Pfizer Inc. (PFE.N)||$33.72||-0.11|
|Novartis AG (NOVN.S)||CHF78.55||+0.45|
|Roche Holding Ltd. (ROG.S)||CHF244.60||+1.10|
|Roche Holding Ltd. (RO.S)||CHF244.90||+0.80|
|GlaxoSmithKline plc (GSK.L)||1,655.00p||+17.50|
Earnings vs. Estimates
Analyst Research Reports
Provider : Thomson Reuters Stock Report
Trading Report for (NKTR). A detailed report, including free correlated market analysis, and updates.
Provider : Stock Traders Daily
Provider : New Constructs, LLC
Provider : ValuEngine, Inc.
Provider : S&P Capital IQ Quantitative Report
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.